...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Expression and clinical significance of absent in melanoma 2 in colorectal cancer
【24h】

Expression and clinical significance of absent in melanoma 2 in colorectal cancer

机译:黑色素瘤2在结肠直肠癌中缺席的表达及临床意义

获取原文
获取原文并翻译 | 示例

摘要

Abstract Increasing research has indicated that absent in melanoma 2 (AIM2) is aberrantly expressed in several tumor types. However, the association between AIM2 expression and clinicopathological factors or prognosis of patient with colorectal cancer (CRC) remains elusive. In the present study, we first examined the protein and mRNA expression of AIM2 in CRC cell lines by western blotting and quantitative RT-PCR (qRT-PCR). Then, we detected AIM2 expression in CRC tissue using western blotting and immunohistochemistry (IHC) respectively to evaluate its clinicopathological characteristics and prognosis in CRC. Our cytological experiments showed that there was low AIM2 expression in most of the CRC cell lines. Western blotting and IHC indicated that AIM2 expression was obviously lower in the primary CRC tissue than the adjacent normal tissue ( P 0.01 and P 0.001). Clinicopathological analysis revealed that low AIM2 expression was significantly associated with some clinicopathological features such as depth of invasion ( P = 0.020), TNM clinical stage ( P = 0.013) and lymph node metastasis ( P = 0.026). Spearman analysis indicated that there was a negative correlation between AIM2 expression and preoperative serum carcino-embryonic antigen (CEA) levels in CRC patients (r = ?0.217, P = 0.009). Moreover, Kaplan-Meier analysis showed that low expression of AIM2 could lead to a significantly shorter overall survival rate ( P = 0.001). Cox’s proportional hazards model also indicated that the low expression of AIM2 could serve as an independent and significant prognostic factor for survival. Taken together, our findings identify AIM2 as a valuable biomarker for prognosis and a potential therapeutic target for CRC. ]]>
机译:摘要提高研究表明,黑色素瘤2(AIM2)中不存在于几种肿瘤类型中表达。然而,AIM2表达与临床病理因素或具有结直肠癌(CRC)的患者预后的关联仍然难以捉摸。在本研究中,我们首先通过Western印迹和定量RT-PCR(QRT-PCR)检查CRC细胞系中AIM2的蛋白质和mRNA表达。然后,我们使用蛋白质印迹和免疫组织化学(IHC)检测CRC组织中的AIM2表达,以评估其CRC中的临床病理特征和预后。我们的细胞学实验表明,大多数CRC细胞系中的AIM2表达低。蛋白质印迹和IHC表明,初级CRC组织中的AIM2表达明显低于相邻的正常组织(P <0.01和P <0.001)。临床病理分析显示,低AIM2表达与一些临床病理学特征显着相关(P = 0.020),TNM临床阶段(P = 0.013)和淋巴结转移(P = 0.026)。 Spearman分析表明,在CRC患者中AIM2表达和术前血清癌胚抗原(CEA)水平之间存在负相关(R = 0.217,P = 0.009)。此外,Kaplan-Meier分析表明,Aim2的低表达可能导致整体存活率明显缩短(p = 0.001)。 Cox的比例危险模型还表明Aim2的低表达可以作为存活的独立和显着的预后因素。我们的研究结果一起占据了AIM2作为预后和CRC的潜在治疗靶标的助理生物标志物。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号